Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Biologic therapy.

Harvard Medical School, Boston, MA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Boston, MA
Treatments:Chemotherapy, Biologic therapyHospital:Harvard Medical School
Drugs:Journal:Link
Date:Nov 2014

Description:

Patients:
This study involved 42 recurrent glioblastoma patients who were previously treated with bevacizumab. The median patient age was 49 years and 66.7% were male.

Treatment:
Patients received chemotherapy with carmustine or lomustine in combination with the biologic therapy agent bevacizumab.

Toxicities:
The most severe toxicities were of grade 4 and included grade 3-4 thrombocytopenia, neutropenia, and high blood pressure.

Results:
The median overall survival was 4.3 months.

Correspondence: Dr. Eudocia Q. Lee; email: [email protected]



Back